Leonard Kruimer
Chairman at BIOINVENT INTERNATIONAL AB
Net worth: 2 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alf Gunnar Martin Nicklasson | M | 69 | 11 years | |
| Adesh Kaul | M | 50 | 15 years | |
| Sijmen de Vries | M | 65 | 16 years | |
| Björn Frendéus | M | 51 | 23 years | |
| Martin Welschof | M | 63 | 6 years | |
| Domenico Scala | M | 59 | 13 years | |
| Adam Sinding Steensberg | M | 50 | 14 years | |
| Damian Heller | M | 58 | 9 years | |
| Peer Nils Schröder | M | - | - | |
| David Veitch | M | 59 | 10 years | |
| Thomas Werner | M | 68 | 13 years | |
| Ruud van Outersterp | M | 60 | 4 years | |
| Michael Levitan | M | 66 | - | |
| Bernadette Connaughton | F | 65 | 5 years | |
| Marc Engelhardt | M | 60 | 14 years | |
| Ivan M. Møller | M | 52 | 6 years | |
| Kristoffer Bissessar | M | 56 | 6 years | |
| Mireille Sanders | F | 56 | 5 years | |
| Frederik Barfoed Beck | M | 57 | - | |
| Anna Krassowska | F | - | - | |
| Jeffrey Berkowitz | M | 58 | 5 years | |
| Deborah Jorn | F | 66 | 5 years | |
| Vincent Ossipow | M | 55 | 8 years | |
| Cecilia Hofvander | F | - | 3 years | |
| Nicole Onetto | M | 71 | 7 years | |
| Kirsten Drejer | M | 68 | 6 years | |
| Stefan Ericsson | M | 61 | 26 years | |
| Laurenz Kellenberger | M | 57 | 24 years | |
| Anurag Relan | M | 52 | - | |
| Ingunn Munch Lindvig | M | - | 1 years | |
| Thomas Heineman | M | - | 4 years | |
| Stephen Toor | M | 52 | 4 years | |
| Christina Sonnenborg Bredal | F | 39 | 4 years | |
| Natalie Berner | F | 34 | 2 years | |
| Anneline Nansen | F | 55 | 3 years | |
| Marie Moores | F | - | 2 years | |
| Dung Tran Ngoc | F | - | - | |
| Henriette Wennicke | F | - | 2 years | |
| Martin Pålsson | M | 45 | 2 years | |
| Emma Meurling | F | - | - | |
| Ravinder Chahil | M | 56 | - | |
| Bernd Seizinger | M | 67 | 6 years | |
| Sylvie Ryckebusch | M | - | 2 years | |
| Gerrit Hauck | M | 60 | 6 years | |
| Jon Patton | M | - | 4 years | |
| Mark Pykett | M | 60 | 4 years | |
| Jeroen Wakkerman | M | 55 | 4 years | |
| Steven Baert | M | 50 | 3 years | |
| Carole A. Sable | M | 62 | 1 years | |
| Nanna Liebach Lüneborg | M | 49 | 2 years | |
| Alain Parthoens | M | 64 |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | 13 years |
| Andres McAllister | M | 68 | 7 years | |
| Barbara Yanni | F | 69 | 4 years | |
| Thomas O. Hecht | M | 73 | 4 years | |
| David M. Kendall | M | 62 | 2 years | |
| Erik Esveld | M | - | 3 years | |
| Kristoffer Rudenholm Hansson | M | 50 | 8 years | |
| Jabine T. M. van der Meijs | M | 58 | 3 years | |
| Richard Peters | M | 61 | 1 years | |
| Ursula Eberhardt | F | 62 | 18 years | |
| James Parsons | M | 58 | 2 years | |
| Elin Birgersson | F | 39 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| René Beukema | M | 60 |
T.I.P. Europe Ltd.
 T.I.P. Europe Ltd. Other TransportationTransportation T.I.P. Europe Ltd. engaged in the operation of warehousing and storage facilities for land transport activities. The company was founded on March 26, 1986 and was headquartered in London, the United Kingdom.
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | 5 years |
| Paul Sekhri | M | 65 | 8 years | |
| Arnold Hoevenaars | M | 74 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | - |
| Michael Oredsson | M | 64 | 5 years | |
| Alain Munoz | M | 75 | 17 years | |
| Michael Owen | M | 73 | 12 years | |
| Marie Paule Richard | M | 72 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | - |
| Aad de Winter | M | 71 | 12 years | |
| Mads Vindahl Kronborg | M | - | - | |
| An van Es-Johansson | M | 64 | 5 years | |
| Ulrika T. Mattson | F | 56 | 10 years | |
| Emmanuel Dulac | M | 55 | 3 years | |
| Rosemary Crane | F | 64 | 4 years | |
| Catherine Moukheibir | F | 64 | 5 years | |
| Steven Skolsky | M | 68 | 15 years | |
| Jane M. Birgitta Stymne Göransson | F | 67 | 2 years | |
| Cees de Jong | M | 63 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | - |
| Elin Jaensson Gyllenbäck | M | 45 | - | |
| William Rice | M | 65 | 6 years | |
| Floris F. Waller | M | 66 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | 2 years |
| Lani Pollworth Morvan | M | - | 2 years | |
| Rie Schultz Hansen | M | - | 3 years | |
| Ronald H. P. Brus | M | 61 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | - |
| Ton Logtenberg | M | 65 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | 3 years |
| Domenico Valerio | M | 67 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | - |
| Lars Ingelmark | M | 75 | 12 years | |
| John Barrie Ward | M | 86 | 14 years | |
| Matthew D. Dallas | M | 49 | 3 years | |
| Iben Louise Gjelstrup | M | 47 | 4 years | |
| George Siber | M | 79 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | 1 years |
| Niklas Prager | M | 54 | 1 years | |
| Jonathan Schatz | M | 67 |
Pricewaterhouse & Co.
| 13 years |
| Kuno Sommer | M | 68 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | - |
| Mark E. Mansour | M | - |
Pricewaterhouse & Co.
| 4 years |
| Carolyn M. Kedersha | F | - |
Pricewaterhouse & Co.
| 3 years |
| Richard Elgin Rooney | M | - |
Pricewaterhouse & Co.
| 2 years |
| Gertrud Koefoed Rasmussen | M | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Netherlands | 27 | 27.27% |
| Sweden | 27 | 27.27% |
| Denmark | 24 | 24.24% |
| Switzerland | 15 | 15.15% |
| Canada | 4 | 4.04% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Leonard Kruimer
- Personal Network